Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023
NEJM Evidence · 2024
DOI: 10.1056/evidoa2400189 ↗Kurz gefasst
Fachartikel in der Zeitschrift NEJM Evidence, 2024. Verfasst von Patricia A Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of Readiness and Response, Centers for Disease Control and Prevention, Atlanta. Hauptthemen laut MEDLINE: Antiviral Agents, Mpox, Monkeypox. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Office of Readiness and Response, Centers for Disease Control and Prevention, Atlanta.
- Booz Allen Hamilton, McLean, VA.
- Cherokee Nation Integrated Health, Tulsa, OK.
- Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta.
Förderung
- Intramural CDC HHS
Zitieren
APA
Yu, P. A., Elmor, R., Muhammad, K., Yu, Y. C., & Rao, A. K. (2024). Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023. NEJM Evidence. https://doi.org/10.1056/evidoa2400189
Vancouver
Yu PA, Elmor R, Muhammad K, Yu YC, Rao AK. Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023. NEJM Evidence. 2024. doi:10.1056/evidoa2400189
BibTeX
@article{Yu2024,
author = {Yu, Patricia A and Elmor, Riad and Muhammad, Kalimah and Yu, Yon C and Rao, Agam K},
title = {Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023},
journal = {NEJM Evidence},
year = {2024},
doi = {10.1056/evidoa2400189}
}
EUVIMED